Objectives: To systematically examine the effectiveness, tolerability, and safety of brexanolone infusion in treating postpartum depression (PPD).
Methods: Randomized controlled trials (RCTs) were included.
Results: Two articles reporting 3 RCTs with 4 active arms (n = 267) covering 156 women with PPD receiving brexanolone infusion and 111 women with PPD on placebo were included. Compared with placebo, women suffering from PPD who received brexanolone had significantly greater response that started after 24 h (risk ratio (RR)=1.34, 95%CI 1.03-1.73), peaked at 36 h (RR = 1.50, 95%CI 1.06-2.13, P = 0.02) and lasted until Day 7 (RR = 1.32, 95%CI 1.01-1.73). Similarly, PPD women treated with brexanolone had significantly greater remission starting at 24 h (RR = 1.86, 95%CI 1.03-3.34), peaking at 60 h (RR = 2.20, 95%CI 1.31-3.70) and lasting until 72 h (RR = 1.96, 95%CI 1.41-2.72). Brexanolone infusion led to significantly higher rate of discontinuation for any reasons (RR = 2.68, 95%CI 1.35-5.32). Discontinuation due to intolerability and adverse drug reactions was similar between the active agent and placebo.
Conclusion: A single brexanolone infusion appears to have ultra-rapid antidepressant effect for PPD, lasting for up to 1 week. The short and long-term therapeutic effect of brexanolone needs to be examined in large-scale RCTs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psychres.2019.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects.
Expert Opin Drug Saf
August 2024
Second Department of Infectious Disease, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Background: Postpartum depression (PPD) is linked to hormonal changes. Brexanolone, the first FDA-approved drug for PPD, is a potential treatment. This study analyzes Brexanolone's safety using the FAERS database, highlighting its adverse effects and potential risk factors.
View Article and Find Full Text PDFAn update on approved and emerging drugs for the treatment of postpartum depression.
Ideggyogy Sz
July 2024
Department of Medical Pharmacology, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey.
Article Synopsis
- Postpartum mental health disorders, including depression and anxiety, often stem from issues like poor relationships, lack of support, low socioeconomic status, and are prevalent in those who experienced depressive symptoms during pregnancy.
- Reproductive hormones, particularly progesterone and its metabolite allopregnanolone, significantly affect mood and mental health during the peripartum period; low levels of allopregnanolone are linked to a higher risk of postpartum depression.
- Synthetic allopregnanolone treatments, Brexanolone and Zuranolone, have been approved for postpartum depression; Brexanolone is given via IV for 60 hours with immediate effects, while Zuranolone is taken orally.
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull
July 2024
Dr. Schatzberg is Kenneth T. Norris, Jr. professor in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine in California.
Article Synopsis
- Several innovative treatments for mental health and neurodegenerative conditions have emerged or are set to be approved, including new antidepressants and drugs targeting PTSD and Alzheimer's disease.
- The new antidepressant Auvelity combines bupropion and dextromethorphan, enhancing efficacy and tolerability compared to bupropion alone, though its comparison to higher doses of bupropion is still uncertain.
- Zuranolone, a recent addition for treating postpartum depression, is more convenient than its predecessor brexanolone due to its oral formulation instead of requiring an intravenous infusion.
Brexanolone Treatment in a Real-World Patient Population: A Case Series and Pilot Feasibility Study of Precision Neuroimaging.
J Clin Psychopharmacol
April 2024
From the Department of Psychiatry, Washington University in St Louis, St Louis, MO.
Purpose/background: Brexanolone is approved for postpartum depression (PPD) by the United States Food and Drug Administration. Brexanolone has outperformed placebo in clinical trials, but less is known about the efficacy in real-world patients with complex social and medical histories. Furthermore, the impact of brexanolone on large-scale brain systems such as changes in functional connectivity (FC) is unknown.
View Article and Find Full Text PDFNovel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions.
Neuropsychopharmacology
January 2024
Department of Psychiatry, UNC Center for Women's Mood Disorders, MacNider Bldg. Suite 304CB #7160, Chapel Hill, NC, 27599-7160, USA.
Article Synopsis
- This article explores new neurosteroid treatments for postpartum depression (PPD), highlighting their development, clinical trial results, and future prospects in the field.
- It specifically covers brexanolone, the first FDA-approved fast-acting antidepressant for PPD, its clinical trials, and the challenges associated with its intravenous administration.
- The article also discusses exciting advancements like zuranolone and ganaxolone, emphasizing the role of GABA signaling and inflammation in depressive disorders to potentially improve treatments for PPD and major depressive disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!